pharmaphorum January 7, 2024
Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that
Using the new LillyDirect service, Zepbound (tirzepatide) will be available to patients who have a prescription for the drug at a price of $550 per month, half the $1,060 list price offered to insurers before discounts or rebates, which is the same price someone without insurance would pay with a Zepbound savings card. It also features direct home delivery.
Organisations like wholesalers and pharmacy benefit managers (PBMs) are still likely to be involved in the supply process for patients with insurance, so the move is not as disruptive as might appear at first glance,...
Today's Sponsors
Today's Sponsor